MedTrace Logo

Evaluation of Anti-venoms Serum in Africa

NCT03326492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 474

Last updated 2025-09-22

No results posted yet for this study

Summary

There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites.

The main objective is to assess the short term tolerance (\< 2 hours post-injection) of the antivenom Inoserp Pan-Africa® (temporary market authorization) from Inosan laboratory currently available in Cameroon.

Conditions

  • Snake Bites
  • Antivenins
  • Snake Venoms

Interventions

DRUG

Antivenom serum Inoserp Pan-Africa® injection

Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.

Sponsors & Collaborators

  • Cameroon Society of Epidemiology (CaSE)

    collaborator UNKNOWN

  • Centre International de Recherches d'Enseignements et de Soins (CIRES)

    collaborator UNKNOWN

  • Centre Pasteur du Cameroun

    collaborator OTHER

  • Inosan Biopharma

    collaborator INDUSTRY

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Armand Nkwescheu, MD · Cameroon Society of Epidemiology, Cameroon

  • Yap Boum, MD · Médecins Sans Frontière

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2021-09-14
Completion
2021-09-14

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03326492 on ClinicalTrials.gov